Results 51 to 60 of about 328,188 (291)

Model-based Prediction of Length of Stay for Rehabilitating Stroke Patients

Journal of the Formosan Medical Association, 2009
Accurate length-of-stay (LOS) estimates have an impact on medical costs for stroke patients. Most studies have reported only descriptive sample means or have provided linear-model-based estimates for LOS.
Chien-Lin Lin, Pao-Hsuan Lin, Li-Wei Chou, Shou-Jen Lan, Nai-Hsin Meng, Sui-Foon Lo, Hong-Dar Isaac Wu   +6 more
doaj   +1 more source

Estimating panel data duration models with censored data [PDF]

, 2008
This paper presents a method for estimating a class of panel data duration models, under which an unknown transformation of the duration variable is linearly related to the observed explanatory variables and the unobserved heterogeneity (or frailty) with
Lee, S.
core   +1 more source

Duration time‐series models with proportional hazard [PDF]

Journal of Time Series Analysis, 2007
Abstract. The analysis of liquidity in financial markets is generally performed by means of the dynamics of the observed intertrade durations (possibly weighted by price or volume). Various dynamic models for duration data have been considered in the literature, such as the Autoregressive Conditional Duration (ACD) model.
Patrick Gagliardini, Christian Gourieroux   +1 more
openaire   +2 more sources

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

Survival in influenza virus-related pneumonia by viral subtype: 2016-2020

International Journal of Infectious Diseases, 2021
Background: : Influenza remains a common cause of morbidity and mortality worldwide, and viral subtype-related differences in disease outcomes have been documented.
Efrén Murillo-Zamora, Xóchitl Trujillo, Miguel Huerta, Mónica Ríos-Silva, José Guzmán-Esquivel, Verónica Benites-Godínez, Oliver Mendoza-Cano   +6 more
doaj   +1 more source

Analysis of time-to-event for observational studies: Guidance to the use of intensity models

, 2020
This paper provides guidance for researchers with some mathematical background on the conduct of time-to-event analysis in observational studies based on intensity (hazard) models.
Abrahamowicz, Michal, Andersen, Per Kragh, Cook, Richard J, Joly, Pierre, Martinussen, Torben, Perme, Maja Pohar, Taylor, Jeremy MG, Therneau, Terry M, van Houwelingen, Hans C   +8 more
core   +1 more source

Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens.
Matthew T. McEvoy, Elizabeth L. Seashore, W. Susan Cheng, Shondra Clay, Jessica A. Casas, Jennifer H. Foster   +5 more
wiley   +1 more source

An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect [PDF]

, 2014
Background: Most randomized controlled trials with a time-to-event outcome are designed and analysed under the proportional hazards assumption, with a target hazard ratio for the treatment effect in mind. However, the hazards may be non-proportional.
D Stark, DR Cox, FMS Barthel, FMS Barthel, KS Thomas, M Schemper, Mahesh KB Parmar, P Royston, P Royston, P Royston, Patrick Royston, PK Andersen, PM Grambsch, TS Mok, WP McGuire   +14 more
core   +2 more sources

Treatment Decision‐Making Roles and Preferences Among Adolescents and Young Adults With Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Decision‐making (DM) dynamics between adolescents and young adults (AYAs) with cancer, parents, and oncologists remain underexplored in diverse populations. We examined cancer treatment DM preferences among an ethnically and socioeconomically diverse group of AYAs and their parents.
Amanda M. Gutierrez, Jill O. Robinson, Wendy A. Allen‐Rhoades, Hadley S. Smith, Isabel Canfield, Rebecca L. Hsu, Sarah R. Scollon, Lauren R. Desrosiers‐Battu, Nicole M. Schneider, Frank Y. Lin, Donald Williams Parsons, Sharon E. Plon, Mary A. Majumder, Janet Malek, Amy L. McGuire   +14 more
wiley   +1 more source

Associations among apolipoproteins, oxidized high-density lipoprotein and cardiovascular events in patients on hemodialysis. [PDF]

PLoS ONE, 2017
Apolipoproteins are associated with survival among patients on hemodialysis (HD), but these associations might be influenced by dysfunctional (oxidized) high-density lipoprotein (HDL).
Hirokazu Honda, Tsutomu Hirano, Masashi Ueda, Shiho Kojima, Shinichi Mashiba, Yasuyuki Hayase, Tetsuo Michihata, Kanji Shishido, Keiko Takahashi, Nozomu Hosaka, Misa Ikeda, Daisuke Sanada, Takanori Shibata   +12 more
doaj   +1 more source